- Home
- NGNE vs IMXI Comparison
NGNE vs IMXI Comparison
Compare NGNE & IMXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- IMXI
- Stock Information
- Founded
- NGNE 2003
- IMXI 1994
- Country
- NGNE United States
- IMXI United States
- Employees
- NGNE N/A
- IMXI N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- IMXI Retail: Computer Software & Peripheral Equipment
- Sector
- NGNE Health Care
- IMXI Technology
- Exchange
- NGNE Nasdaq
- IMXI Nasdaq
- Market Cap
- NGNE 325.3M
- IMXI 278.2M
- IPO Year
- NGNE N/A
- IMXI N/A
- Fundamental
- Price
- NGNE $18.48
- IMXI $14.50
- Analyst Decision
- NGNE Strong Buy
- IMXI Buy
- Analyst Count
- NGNE 7
- IMXI 6
- Target Price
- NGNE $41.86
- IMXI $19.60
- AVG Volume (30 Days)
- NGNE 110.1K
- IMXI 1.3M
- Earning Date
- NGNE 08-11-2025
- IMXI 08-11-2025
- Dividend Yield
- NGNE N/A
- IMXI N/A
- EPS Growth
- NGNE N/A
- IMXI N/A
- EPS
- NGNE N/A
- IMXI 1.65
- Revenue
- NGNE N/A
- IMXI $642,149,000.00
- Revenue This Year
- NGNE N/A
- IMXI N/A
- Revenue Next Year
- NGNE N/A
- IMXI $1.87
- P/E Ratio
- NGNE N/A
- IMXI $8.81
- Revenue Growth
- NGNE N/A
- IMXI N/A
- 52 Week Low
- NGNE $6.88
- IMXI $8.58
- 52 Week High
- NGNE $74.49
- IMXI $22.37
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- IMXI 75.35
- Support Level
- NGNE $19.59
- IMXI $14.34
- Resistance Level
- NGNE $20.46
- IMXI $14.55
- Average True Range (ATR)
- NGNE 1.23
- IMXI 0.19
- MACD
- NGNE -0.20
- IMXI -0.01
- Stochastic Oscillator
- NGNE 13.37
- IMXI 19.05
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About IMXI International Money Express Inc.
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.